clinical trial · NCT07247084
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Eli Lilly and Company·phase4·recruiting·n = 3,000
ObesityTirzepatideStandard of Care
brief summary
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
started
Nov 24, 2025
primary completion
Jul 1, 2029
completion
Jul 1, 2032
last updated
Apr 17, 2026
official title
A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol